ABO and Rh Blood Group Frequencies in Acute Leukemia Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Acute Leukemia (Including Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia). Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Evaluation of ABO and Rh Blood Group Frequencies in Acute Leukemia
Overview
This retrospective observational study aims to evaluate the distribution of ABO and Rh blood groups among patients diagnosed with acute leukemia. By analyzing medical records from leukemia cases, the study seeks to identify any potential associations between blood group types and the occurrence of the disease.
Detailed description
Acute leukemia is a group of hematologic malignancies characterized by the rapid proliferation of immature blood cells, leading to bone marrow failure and systemic complications. It is broadly classified into two main types: acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), depending on the lineage of the malignant cells. Despite advancements in the understanding of leukemia pathogenesis, the etiology remains multifactorial and incompletely understood.
Recent studies have suggested a potential association between blood group antigens-particularly those of the ABO and Rh systems-and the risk of developing various types of cancer, including hematological malignancies. The ABO antigens are expressed not only on red blood cells but also on epithelial and endothelial cells, and may influence cancer biology through mechanisms involving immune response modulation, cell adhesion, and inflammation.
Several epidemiological investigations have explored the relationship between ABO and Rh blood groups and malignancies such as gastric, pancreatic, breast, and hematologic cancers. However, data regarding their association with acute leukemia are still limited, inconsistent, and often vary across different populations and study designs.
This study is a retrospective observational analysis conducted at the Clinical Pathology Department, South Egypt Cancer Institute, Assiut University. It aims to assess the frequencies of ABO and Rh blood groups among patients diagnosed with acute leukemia over a defined period. The findings will be compared to blood group distributions in healthy blood donors to explore any statistically significant associations.
Understanding whether certain blood group antigens are associated with an increased or decreased risk of acute leukemia may help identify at-risk individuals, contribute to risk stratification, and provide further insight into the biology of leukemogenesis.
Primary outcome measures
- Frequency distribution of ABO and Rh blood groups among acute leukemia patients [Time frame: Between 2022 and 2025]
Secondary outcome measures (1)
- Association between blood group types and leukemia subtype [Time frame: Between 2022 and 2025]
Eligibility criteria
Inclusion criteria
- Patients diagnosed with de-novo acute leukemia (ALL or AML)
- Diagnosis confirmed between 2022 and 2025
- ABO and Rh blood group data available
- Patients treated at or referred to South Egypt Cancer Institute, Assiut University
Exclusion criteria
- Incomplete or missing blood group data
- Presence of other malignancies or chronic systemic illnesses
- History of blood transfusion prior to diagnosis or blood grouping
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
Egypt · 1 center
- South Egypt Cancer Institute - Assiut University — Asyut
Identifiers
NCT: NCT07108010 · Blood group in Acute Leukemia